BACKGROUND
Diabetes is a known risk factor, and a distinct form termed pancreatic cancer-related diabetes (PCRD) often precedes the diagnosis of cancer by 3-5 years, offering a potential window for intervention. We hypothesised that interactions between stromal pancreatic stellate cells (PSCs) and cancer cells trigger...
Rohit Sarkar, C. Perera, M. J. Hossain et al.· Pancreatology : official jou...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with a five-year survival rate of just 13%. For the >80% of patients presenting with metastatic disease, standard-of-care systemic chemotherapies such as FOLFIRINOX or gemcitabine/nab-paclitaxel (GnP) inevitably induce resistance, frequently forci...
Brooke A. Pereira, Katie A. Gordon, Victoria M. Tyma et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal and metastatic malignancy, with standard-of-care treatments, such as gemcitabine/nab-paclitaxel (GnP) offering limited improvement for patients with advanced disease. We and others have shown that co-targeting key factors in combination with chemotherapy...
Shona Ritchie, Victoria M. Tyma, Shanna Hafiz et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.